Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical officer at the start of this year after the company’s oncology department suffered some prominent setbacks. The run of bad ...

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...

Corsico now serves as Sanofi’s global head of development, taking on a role that sat vacant since Gilead Sciences plucked Dietmar Berger, M.D., Ph.D., to replace Chief Medical Officer Merdad ...

Berger said there are early signs that the combination may also help patients live longer, but the data is still new. Gilead is also studying Trodelvy as a first-line treatment in another type of ...